Sunday 11 October 2026 Export all SNY data to Excel Powerpack

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

40.07 0.16 −0.40%
Market cap
$95.9B
P/E
21.0×
Fwd P/E
—
Dividend yield
6.05%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
58/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
22.34 13.46 13.46 11.29

+8 more quarters

P/S ratio
1.79 2.12 2.24 2.46
P/FCF ratio
7.02 6.24 6.36 13.00
P/Operating CF
18.91 9.54 9.73 62.81
P/B ratio
1.26 1.43 1.46 1.44
EV/Sales
2.11 2.39 2.47 2.73
EV/EBITDA
11.54 13.31 13.29 13.10
EV/FCF
8.25 7.03 7.02 14.45
Current Ratio
0.99 1.01 1.09 1.06
Net Debt/EBITDA
7.13 6.08 10.99 2.97
Debt/Equity
0.31 0.25 0.26 0.27
Earnings Yield
4.48% 7.43% 7.43% 8.86%
Free Cash Flow Yield
14.24% 16.04% 15.73% 7.69%
Free Cash Flow per Share
2.26 0.00 4.98 0.00
Book value per Share
33.80 35.55 33.24 35.28
Free Cash Flow
5,398.42 — 12,162.55 —
EV/EBIT
11.54 13.31 13.29 13.10
Other line items

Show all line items

Columns are period end dates